Union Plus Biotech Group (00690.HK): Ophthalmic drug Kin Yinkang approved for listing

Financial news from Wisenews app, Link Health Group (00690.HK) announced that the National Medical Products Administration (NMPA) of China has approved the listing application of the group's new ophthalmic product JinYinKang (Diquafosol Sodium Eye Drops) on May 21, 2025, with approval number of "National Drug Approval H20254149". The approval of JinYinKang marks the further improvement of the group's ophthalmic drug pipeline, providing more diversified treatment options for patients with dry eye syndrome.